Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study.

BMC cancer·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Post-Chemoradiation Lymphopenia and Baseline Eosinophil Counts as Prognostic Markers in Glioblastoma.

Research square·2025
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025
Same author

Targeting Glioblastoma Cell State Plasticity for Enhanced Therapeutic Efficacy.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jun 15, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab for malignant gliomas.

Fabio M Iwamoto1, Howard A Fine

  • 1Neuro-Oncology Branch, National Cancer Institute, National Institute for Neurological Disorders and Stroke, National Institutes of Health, 9030 Old Georgetown Rd, Bloch Bldg 82, Room 225, Bethesda, MD 20892, USA.

Archives of Neurology
|March 10, 2010
PubMed
Summary

Malignant gliomas, aggressive brain tumors, often recur despite standard treatment. Anti-angiogenic therapies like bevacizumab show promise for improving outcomes in recurrent glioblastomas.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Experiment Videos

Last Updated: Jun 15, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Vascular Biology

Background:

  • Malignant gliomas are aggressive primary brain tumors with poor prognoses.
  • Despite multimodal treatment (surgery, radiotherapy, temozolomide), tumor recurrence is common.
  • Understanding tumor angiogenesis is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To review the role of tumor angiogenesis in malignant gliomas.
  • To discuss the efficacy of anti-angiogenic therapies, specifically bevacizumab, in recurrent glioblastomas.

Main Methods:

  • Literature review of studies on malignant glioma biology and treatment.
  • Analysis of clinical trial data for bevacizumab in recurrent glioblastomas.

Main Results:

  • Malignant gliomas exhibit significant vascularization, making them targets for anti-angiogenic drugs.
  • Bevacizumab has demonstrated notable activity in recurrent glioblastomas, leading to FDA approval.
  • Other anti-angiogenic agents are under investigation in clinical trials.

Conclusions:

  • Targeting tumor angiogenesis represents a promising therapeutic avenue for malignant gliomas.
  • Bevacizumab offers a new treatment option for patients with recurrent glioblastomas.
  • Further research into anti-angiogenic therapies is warranted to improve patient outcomes.